Innovative Therapeutics in Oncology and Neuroscience
3
...Continuing To Expand our Pipeline Globally and Regionally with Our
Proven BD Expertise
Outstanding BD track record driven by deep scientific rigor
Asset
Once-daily oral
Zejula
niraparib
Bemarituzumab
Zipalertinib
AUGTYRO
(repotrectinib)
tivdak
tisotumab vedotin-tftv
for injection 40 mg
KRAZATI
KarXT
xanomeline-trospium
and strong market insight
Original partner
TESARO
FivePrÃme
cullinan
ONCOLOGY
Turning Point
Therapeutics'
Seagen
MIRATI
THERAPEUTICS
KARUNA
THERAPEUTICS
M&A by...
gsk
AMGEN
TAIHO TAIHO PHARMA
ll Bristol Myers Squibb
2Pfizer
Bristol Myers Squibb
*
Bristol Myers Squibb
Ongoing strategy:
Leverage strong capability to
identify and develop global assets
Continue to identify regional
opportunities with FIC BIC
potential
Opportunistic to strategic
partnership to create share-
holder value
14
All demonstrated positive study results
Many assets were in-licensed at early clinical stage
Abbreviations: first-in-class (FIC), best-in-class (BIC).
Note: The trademarks and registered trademarks within are the property of their respective owners. * Previously announced proposed acquisition of Karuna by Bristol Myers Squibb expected to close in the first half of 2024.
zaiLabView entire presentation